Selenium-Binding Protein 1 Deficiency Inhibits the Antitumor Immunity of Dendritic Cells

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Selenium-binding protein 1 (SELENBP1) is linked to better prognosis in colitis and colon cancer.
• SELENBP1-deficient dendritic cells (DCs) promote regulatory T cell differentiation and immune modulation.
• The role of SELENBP1 in DC-mediated antitumor immunity, particularly T cell activation and exhaustion, requires further investigation.

Purpose of the Study:

• To investigate the role of SELENBP1 in DCs in mediating antitumor immune function.
• To determine if SELENBP1-deficient DCs affect CD8+ T cell activation or exhaustion.
• To explore the underlying molecular mechanisms of SELENBP1's impact on DC function and T cell responses.

Main Methods:

• Utilized mouse models of colon cancer with SELENBP1 deficiency in DCs.
• Conducted adoptive-transfer experiments with SELENBP1-deficient DCs.
• Performed in vitro cell experiments to analyze DC migration, maturation, and CD8+ T cell phenotypes.
• Investigated the involvement of PI3K/AKT and HIF-1α pathways.

Main Results:

• SELENBP1 deficiency accelerated colon cancer progression in mice.
• Reduced numbers of activated DCs and cytotoxic CD8+ T cells were observed in SELENBP1-deficient tumors.
• SELENBP1 deficiency impaired DC antitumor activity, leading to increased T cell exhaustion and reduced tumor-killing capacity.
• In vitro studies identified PI3K/AKT and HIF-1α pathways as involved in DC dysfunction and T cell impairment.

Conclusions:

• SELENBP1 deficiency in DCs impairs their migration and maturation.
• This impairment results in decreased cytotoxic CD8+ T cells and increased dysfunctional T cell phenotypes.
• SELENBP1 deficiency in DCs compromises DC-mediated antitumor immune function, contributing to accelerated colon tumor progression.